NASDAQ$JBIO
Jade Biosciences Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Aerovate Therapeutics, Inc. reported a net loss of $2.518 million and a comprehensive loss of $2.573 million for the three months ended March 31, 2025, with no revenue generated.
Aerovate Therapeutics, Inc. reported a significant reduction in operating expenses for the three months ended March 31, 2025, primarily due to the discontinuation of clinical operations and workforce reduction. The company incurred a net loss of $2.518 million, a substantial improvement from the $23.186 million net loss in the prior year. No revenue was generated, consistent with the company's current operational focus.
- Net loss significantly decreased to $2.518 million in Q1 2025 from $23.186 million in Q1 2024.
- Research and development expenses were $0.0 in Q1 2025, down from $20.080 million in Q1 2024, due to the halt of AV-101 development.
- General and administrative expenses decreased to $3.387 million in Q1 2025 from $4.538 million in Q1 2024, driven by reduced headcount related costs.
- The company had cash and cash equivalents of $44.220 million and total assets of $77.533 million as of March 31, 2025.
Headline financials
Revenue & EPS history
Aerovate · Revenue · Quarterly
$0
Forward guidance
Management believes current cash and short-term investments will fund operations for at least twelve months, but future capital requirements depend on the Merger's success and potential future product development.
Tailwinds
- Current cash and cash equivalents are expected to provide sufficient funds for at least twelve months.
- The proposed merger with Jade is anticipated to be completed, which could provide strategic benefits.
- The company has a remaining ATM program capacity of $6.0 million for potential future sales of common stock.
- The significant reduction in operating expenses, particularly R&D, is expected to improve financial efficiency.
- The company's focus on maximizing shareholder value through strategic alternatives.
Headwinds
- The company has no products approved for commercial sale and does not anticipate generating revenue in the near future.
- Future operations are highly dependent on the successful consummation of the Merger, which is subject to customary closing conditions.
- The company may require additional capital to finance operations, which may not be available on favorable terms or at all.
- The process of completing the Merger may be costly, time-consuming, and complex, potentially diverting management's attention.
- If the Merger is not completed, the company's board may pursue dissolution and liquidation, which could result in stockholders losing all or a significant portion of their investment.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2025
-1.6%
Avg return
Earnings day
-2.1%
Avg return
5 days after
+2.6%
Avg return
30 days after
56%
10 / 18 earnings
Positive
+24.6%
Q3 2023
Best reaction
-35.0%
Q3 2021
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | +1.2% | +1.0% | +11.6% | |
| Q2 2025 | +0.1% | -0.5% | +4.9% | |
| Q1 2025 | +1.8% | -0.3% | -4.8% | |
| Q4 2024 | +0.4% | +0.4% | -85.8% | |
| Q3 2024 | +0.0% | -3.8% | -2.7% | |
| Q1 2024 | -2.8% | +3.7% | +16.1% | |
| Q4 2023 | -0.5% | +14.7% | -17.8% | |
| Q3 2023 | +24.6% | +27.6% | +68.5% | |
| Q2 2023 | -3.5% | -6.0% | -10.8% | |
| Q1 2023 | -7.6% | -12.2% | -19.8% | |
| Q4 2022 | +0.7% | +1.7% | +9.4% | |
| Q3 2022 | +0.6% | -7.1% | +32.9% | |
| Q2 2022 | -13.7% | -17.3% | -26.4% | |
| Q1 2022 | -6.3% | +0.7% | -5.9% | |
| Q4 2021 | +8.0% | -4.8% | -24.9% | |
| Q3 2021 | -35.0% | -33.8% | -42.7% | |
| Q1 2021 | +1.8% | -1.0% | +72.5% | |
| Q2 2021 | +1.8% | -1.0% | +72.5% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro